Tris Pharma, Inc Expands Its Voluntary Nationwide Retail Recall of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, Due to Higher Concentration of Ibuprofen.
"No adverse events have been reported to Tris Pharma Inc., but ibuprofen concentrations have been found as high as 10% above the specified limit, according to the company. The higher potency could cause nausea, vomiting, diarrhea, tinnitus, headache and gastrointestinal bleeding, according to the company. Infants may be more vulnerable to permanent kidney damage."
-American Academy of Pediatrics
Please use the following links to learn more:
FDA- Images and Details https://www.fda.gov/Safety/Recalls/ucm630112.htm
AAP- Announcement http://www.aappublications.org/news/2019/01/31/ibuprofenrecall013119